Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
| Mentioned: | ADAP |
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
No comments:
Post a Comment